Skip to content
Peptigraph home
Shop Peptides50% off*

Orforglipron Benefits: Claims vs What Studies Show

Benefits people claim for Orforglipron, set against what published studies measured, and where no study exists.

Medical review pendingOral small-molecule GLP-1 agonistUpdated
Strongest evidence
Human RCT
Human / animal studies
14 / 0
in our evidence file (PubMed search, 2 Oct 2026)
FDA status
Approved (Foundayo, Apr 2026)
1 Apr 2026

Claimed benefits and what studies show

Each row is an area where people claim a benefit, with the strongest study we summarise behind it. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.

Orforglipron claimed benefits and the studies behind them
ClaimBest evidenceStudies (human / animal)What was measuredPage
Weight lossHuman RCT evidence, 4 of 48 / 0Body weight change; Maintenance of weight reduction after tirzepatide; Maintenance of weight reduction after semaglutideEvidence for weight loss
DiabetesHuman RCT evidence, 4 of 46 / 0Body weight change; Glycaemic control vs oral semaglutide; Glycaemic control vs dapagliflozinEvidence for diabetes
Heart healthHuman RCT evidence, 4 of 42 / 0Cardiometabolic measures; Blood pressure, lipids and hsCRPEvidence for heart health
InflammationHuman RCT evidence, 4 of 41 / 0Blood pressure, lipids and hsCRPEvidence for inflammation

Strongest study per claim: Weight loss, Lancet 2026, PMID 41275875; Diabetes, Lancet 2026, PMID 41275875; Heart health, The New England journal of medicine 2025, PMID 40960239.

What the studies measured

Orforglipron outcomes in published studies
OutcomeResultStudy typeSource
Body weight changeIn people with diabetes, bodyweight changed by -5·1% (6 mg), -7·0% (12 mg) and -9·6% (36 mg) with orforglipron vs -2·5% with placebo at week 72.Human RCTn = 1613Lancet 2026, PMID 41275875
Glycaemic control vs oral semaglutideGlycated hemoglobin changed by -1·71% (orforglipron 12 mg) and -1·91% (36 mg) vs -1·23% (semaglutide 7 mg) and -1·47% (14 mg) at week 52.Human controlled trialn = 1698Lancet 2026, PMID 41765029
Glycaemic control vs dapagliflozinGlycated hemoglobin fell by 1·23%, 1·50% and 1·56% (orforglipron 3, 12, 36 mg) vs 0·81% with dapagliflozin 10 mg.Human controlled trialn = 962Lancet 2026, PMID 42259339
Maintenance of weight reduction after tirzepatideAfter prior tirzepatide, orforglipron maintained an estimated 74.7% of body weight reduction vs 49.2% with placebo.Human RCTn = 376Nature medicine 2026, PMID 42120723
Maintenance of weight reduction after semaglutideAfter prior semaglutide, orforglipron maintained an estimated 79.3% of body weight reduction vs 37.6% with placebo.Human RCTn = 376Nature medicine 2026, PMID 42120723
Weight change in older adultsIn older adults without diabetes, weight changed by -7.9%, -11.3% and -13.0% with orforglipron vs -1.6% with placebo at week 72.Human RCTn = 616Obesity pillars 2026, PMID 42577069
Body weight changeBody weight changed by -7.5% (6 mg), -8.4% (12 mg) and -11.2% (36 mg) with orforglipron vs -2.1% with placebo at week 72.Human RCTn = 3127The New England journal of medicine 2025, PMID 40960239
Weight reduction thresholds at highest doseIn the 36-mg group, 54.6%, 36.0% and 18.4% lost at least 10%, 15% and 20% of body weight, vs 12.9%, 5.9% and 2.8% on placebo.Human RCTn = 3127The New England journal of medicine 2025, PMID 40960239
Cardiometabolic measuresWaist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol significantly improved versus placebo.Human RCTn = 3127The New England journal of medicine 2025, PMID 40960239
Glycated hemoglobin changeGlycated hemoglobin fell by 1.24, 1.47 and 1.48 percentage points (3, 12, 36 mg) vs 0.41 with placebo at week 40.Human RCTn = 559The New England journal of medicine 2025, PMID 40544435
Body weightBody weight changed by -4.5%, -5.8% and -7.6% (3, 12, 36 mg) vs -1.7% with placebo.Human RCTn = 559The New England journal of medicine 2025, PMID 40544435
Blood pressure, lipids and hsCRPBlood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3 and hsCRP decreased significantly versus placebo (exploratory analysis).Human RCTn = 595Cardiovascular diabetology 2025, PMID 40481478
Food effect on exposureExposure (AUC and Cmax) was lower by 23.7% and 23.2% in study A and by 17.6% and 20.9% in study B in the fed state.Human RCTn = 46Diabetes therapy 2024, PMID 38402332
Clinical relevance of food effectThe authors judged the food-related exposure differences unlikely to affect efficacy meaningfully.Human RCTn = 46Diabetes therapy 2024, PMID 38402332
Body weight changeBody weight changed by -8.6% to -12.6% at week 26 and -9.4% to -14.7% at week 36 with orforglipron, vs -2.0% and -2.3% with placebo.Human RCTn = 272The New England journal of medicine 2023, PMID 37351564
Glycaemic control and body weightGlycated hemoglobin fell by up to 2·10% with orforglipron vs 0·43% with placebo and 1·10% with dulaglutide at week 26.Human RCTn = 383Lancet 2023, PMID 37369232
Short-term weight changeBody weight fell by up to 5.4 kg after 4 weeks with orforglipron vs 2.4 kg with placebo.Human RCTn = 92Diabetes, obesity & metabolism 2023, PMID 37344954
Glycated hemoglobin and weightGlycated hemoglobin changed by -1.5% to -1.8% with orforglipron vs -0.4% with placebo; body weight changed by -0.24 to -5.8 kg vs 0.5 kg.Human RCTn = 68Diabetes, obesity & metabolism 2023, PMID 37264711
Absolute oral bioavailabilityMean absolute oral bioavailability of orforglipron was 79.1%.Human uncontrolled trialClinical pharmacology in drug development 2026, PMID 40888509
Route of eliminationElimination was mainly via feces (87%) with minimal urinary excretion (0.2%).Human uncontrolled trialClinical pharmacology in drug development 2026, PMID 40888509

Showing the first 20 of 21 rows, strongest sources first.

Not shown in any study we cite. Searches behind this page: PubMed search on 2 Oct 2026 for “orforglipron[tiab] OR LY3502970[tiab]”: 145 results. PubMed search on 2 Oct 2026 for “orforglipron[tiab] AND (randomized controlled trial[pt] OR clinical trial[pt] OR phase 3)”: 44 results. PubMed search on 2 Oct 2026 for “orforglipron[tiab] AND (pharmacokinetic*[tiab] OR half-life[tiab] OR "healthy" )”: 19 results.

Claimed: weight loss from a daily pill

In a 3127-patient phase 3 trial in adults with obesity, mean body weight changed -7.5% with 6 mg, -8.4% with 12 mg and -11.2% with 36 mg of orforglipron against -2.1% with placebo at week 72.[6]

The Foundayo label approves it as an adjunct to diet and activity to reduce excess body weight and maintain weight reduction in adults with obesity or overweight with a weight-related condition.[18]

Claimed: better blood sugar

In a phase 2 trial in adults with type 2 diabetes, HbA1c changed by up to -2.10% with orforglipron against -0.43% with placebo and -1.10% with dulaglutide at week 26.[11]

Against dapagliflozin, HbA1c fell 1.23%, 1.50% and 1.56% with orforglipron 3 mg, 12 mg and 36 mg versus 0.81% with dapagliflozin 10 mg.[3]

Claimed: heart and blood-pressure benefits

In the obesity trial, waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol improved significantly with orforglipron compared with placebo.[6]

The label records the other side: a mean increase in heart rate of 4 to 5 beats per minute versus 0.5 with placebo.[18]

Claimed: lower inflammation

A pooled analysis of two phase 2 trials reported placebo-adjusted decreases in blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3 and hsCRP, an inflammation marker, with orforglipron.[8]

Honest limits

The head-to-head trial with oral semaglutide found more gastrointestinal events, discontinuations and pulse-rate increase with orforglipron.[2]

In a maintenance study, participants who reached a weight plateau kept a model-based estimate of 74.7% of their weight reduction on orforglipron.[4]

More on Orforglipron

DosageSide effectsResultsHow it works

Common questions

Is Orforglipron proven to work?

The strongest study we summarise for Orforglipron is human rct evidence, among 15 studies. A trial result is not an approval; see the legal status.

Does orforglipron work?

Phase 3 trials reported larger weight and HbA1c changes than placebo, and the drug carries an FDA label for weight management.[6]

More on Orforglipron

DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.ResultsStudy outcomes and when they were measured.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.How it worksTarget, mechanism and how long it acts, from the label or studies.

Sources

  1. 1Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
  2. 2Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 41765029Accessed 2 Oct 2026
  3. 3Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.Lancet (London, England) · 2026PMID 42259339Accessed 2 Oct 2026
  4. 4Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.Nature medicine · 2026PMID 42120723Accessed 2 Oct 2026
  5. 5Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.Obesity pillars · 2026PMID 42577069Accessed 2 Oct 2026
  6. 6Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
  7. 7Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544435Accessed 2 Oct 2026
  8. 8Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.Cardiovascular diabetology · 2025PMID 40481478Accessed 2 Oct 2026
  9. 9Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024PMID 38402332Accessed 2 Oct 2026
  10. 10Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.The New England journal of medicine · 2023PMID 37351564Accessed 2 Oct 2026
  11. 11Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.Lancet (London, England) · 2023PMID 37369232Accessed 2 Oct 2026
  12. 12Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.Diabetes, obesity & metabolism · 2023PMID 37344954Accessed 2 Oct 2026
  13. 13Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.Diabetes, obesity & metabolism · 2023PMID 37264711Accessed 2 Oct 2026
  14. 14Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants.Clinical pharmacology in drug development · 2026PMID 40888509Accessed 2 Oct 2026
  15. 15PubMed search: orforglipron[tiab] OR LY3502970[tiab] (145 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16PubMed search: orforglipron[tiab] AND (randomized controlled trial[pt] OR clinical trial[pt] OR phase 3) (44 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17PubMed search: orforglipron[tiab] AND (pharmacokinetic*[tiab] OR half-life[tiab] OR "healthy" ) (19 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  18. 18FOUNDAYO prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026

Found an error? Report a correction.